Potential drug–drug interactions associated with drugs currently proposed for COVID‐19 treatment in patients receiving other treatments
F. Lemaı̂tre, Caroline Solas, Matthieu Grégoire, Laurence Lagarce, Laure Elens, Élisabeth Polard, Béatrice Saint–Salvi, Agnès Sommet, Michel Tod, Chantal Barin‐Le Guellec
Abstract
Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.
Topics & Concepts
DrugMedicineCoronavirus disease 2019 (COVID-19)Intensive care medicineDrug treatmentPharmacotherapy2019-20 coronavirus outbreakDrug interactionPharmacologyClinical trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineDiseasePathologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesPharmacological Receptor Mechanisms and EffectsAntibiotics Pharmacokinetics and Efficacy